Tongli Pharmaceuticals (USA), Inc. (TGLP) Financial Statements (2026 and earlier)

Company Profile

Business Address 125 MAIDEN LANE, SUITE 309
NEW YORK, NY 10038
State of Incorp. DE
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2013
Q3
9/30/2013
Q2
6/30/2013
Q1
3/31/2013
Q4
12/31/2012
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments45378197
Cash and cash equivalent45378197
Receivables1,2622,3042,9662,473
Inventory, net of allowances, customer advances and progress billings272738999
Inventory272738999
Advances on inventory purchases384244277
Deposits current assets    1,270
Prepaid expense and other current assets1144
Other undisclosed current assets58453957995
Total current assets:1,9552,9494,0704,354
Noncurrent Assets
Property, plant and equipment5,8955,9515,9536,009
Intangible assets, net (including goodwill)3,2233,2653,2775,252
Intangible assets, net (excluding goodwill)3,2233,2653,2775,252
Prepaid expense38  
Deposits noncurrent assets10,5349,6718,7616,023
Total noncurrent assets:19,69018,88717,99017,285
TOTAL ASSETS:21,64521,83722,06021,639
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4006461,332995
Taxes payable250225765685
Accounts payable13248355118
Accrued liabilities137173212192
Due to related parties432318261180
Total current liabilities:8329641,5931,175
Noncurrent Liabilities
Total liabilities:8329641,5931,175
Equity
Equity, attributable to parent20,81320,87320,46720,463
Common stock15151515
Additional paid in capital9,1219,1079,0949,056
Accumulated other comprehensive income2,8942,7692,4562,350
Retained earnings8,7838,9828,9029,043
Total equity:20,81320,87320,46720,463
TOTAL LIABILITIES AND EQUITY:21,64521,83722,06021,639

Income Statement (P&L) ($ in thousands)

12/31/2013
Q3
9/30/2013
Q2
6/30/2013
Q1
3/31/2013
Q4
12/31/2012
Q3
Revenues
(Revenue, Net)
  7514,0223,753
Cost of revenue
(Cost of Product and Service Sold)
  (379)(2,024)(1,733)
Other undisclosed gross profit   9 
Gross profit:  3722,0072,020
Operating expenses(229)(236)(2,095)(226)
Operating income (loss):(229)135(88)1,794
Nonoperating expense(15)(13)(72)(10)
Other nonoperating income2424 16
Interest and debt expense(14)(13)(37)1
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes141337(1)
Income (loss) from continuing operations before income taxes:(244)122(160)1,784
Income tax expense (benefit)44(42)20(469)
Income (loss) from continuing operations:(200)79(140)1,315
Income (loss) before gain (loss) on sale of properties:(200)79(140)1,315
Net income (loss) available to common stockholders, diluted:(200)79(140)1,315

Comprehensive Income ($ in thousands)

12/31/2013
Q3
9/30/2013
Q2
6/30/2013
Q1
3/31/2013
Q4
12/31/2012
Q3
Net income (loss):(200)79(140)1,315
Comprehensive income (loss):(200)79(140)1,315
Other undisclosed comprehensive income, net of tax, attributable to parent12431310671
Comprehensive income (loss), net of tax, attributable to parent:(75)393(34)1,386

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: